TY - JOUR
T1 - Synthesis and in vitro evaluation of new TRPV4 ligands and biodistribution study of an 11C-labeled radiotracer in rodents
AU - Qiu, Lin
AU - Du, Lixia
AU - Liang, Qianwa
AU - Hu, Hongzhen
AU - Tu, Zhude
N1 - Funding Information:
This work was supported by the USA National Institutes of Health including the National Institute of Neurological Disorders and Stroke, and the National Institute of Aging [NS075527 and NS103957. Dr. Hongzhen Hu was supported by grants from the NIH, R01DK103901 and R01AA027065, Washington University School of Medicine Digestive Disease Research Core Center (NIDDK P30 DK052574), The Center for the Study of Itch of the Department of Anesthesiology at Washington University School of Medicine.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/11/15
Y1 - 2020/11/15
N2 - Nine new compounds targeting the transient receptor potential vanilloid-4 (TRPV4) were synthesized and their biological activities toward TRPV4 were determined using freshly isolated mouse skin macrophages through live cell Ca2+ imaging assay. Three compounds 4b, 4c, and 4i exhibited higher percentages of in vitro activation of TRPV4 as 48.1%, 59.3% and 33.5%, which are comparable to 56.4% activation response of the reported TRPV4 agonist GSK1016790A (3). The compound 4i was chosen for 11C-radiosynthesis using its phenol precursor 4g to reacted with [11C]methyl iodide. The radiosynthesis was achieved with good radiochemical yield (16 ± 5%), high chemical and radiochemical purity (>95%), and high molar activity (16–21 GBq/μmol, decay corrected to the end of bombardment, EOB n ≥ 4). Furthermore, the initial ex vivo biodistribution study in rats showed that [11C]4i had higher uptake in kidney, liver and small intestine compared to other tissues with rapid washout.
AB - Nine new compounds targeting the transient receptor potential vanilloid-4 (TRPV4) were synthesized and their biological activities toward TRPV4 were determined using freshly isolated mouse skin macrophages through live cell Ca2+ imaging assay. Three compounds 4b, 4c, and 4i exhibited higher percentages of in vitro activation of TRPV4 as 48.1%, 59.3% and 33.5%, which are comparable to 56.4% activation response of the reported TRPV4 agonist GSK1016790A (3). The compound 4i was chosen for 11C-radiosynthesis using its phenol precursor 4g to reacted with [11C]methyl iodide. The radiosynthesis was achieved with good radiochemical yield (16 ± 5%), high chemical and radiochemical purity (>95%), and high molar activity (16–21 GBq/μmol, decay corrected to the end of bombardment, EOB n ≥ 4). Furthermore, the initial ex vivo biodistribution study in rats showed that [11C]4i had higher uptake in kidney, liver and small intestine compared to other tissues with rapid washout.
KW - Analogues
KW - Biodistribution
KW - PET
KW - Radiosynthesis
KW - TRPV4
UR - http://www.scopus.com/inward/record.url?scp=85091778828&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2020.127573
DO - 10.1016/j.bmcl.2020.127573
M3 - Article
C2 - 32980513
AN - SCOPUS:85091778828
SN - 0960-894X
VL - 30
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 22
M1 - 127573
ER -